Full Schedule

08:00 – 09:25 CEST

Session XX: Presentation of Selected Abstracts: Metastatic Colorectal Cancer

Chair: – Rambam Health Care Campus

Chair: – Odense University Hospital

08:00 – 08:08 CEST

SO-24: Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: overall survival and subgroup analysis of the randomized phase 2 VELO trial

Abstract Presenter:

08:08 – 08:16 CEST

SO-25: Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment for RAS and BRAF wild-type metastatic colorectal cancer: Updated survival analysis of the DEEPER trial by JACCRO

Abstract Presenter: – St. Marianna University School of Medicine

08:16 – 08:24 CEST

SO-26: Intermittent or continuous panitumumab plus FOLFIRI for first-line treatment of patients with RAS/BRAF wild-type metastatic colorectal cancer: an update of survival/toxicity and preliminary results of genomic alterations from IMPROVE study

Abstract Presenter:

08:24 – 08:32 CEST

SO-27: Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: results of the phase II AVETRIC trial by GONO

Abstract Presenter:

08:32 – 08:42 CEST

Discussant: SO-24, SO-25, SO-26, SO-27

Discussant: – King Faisal Specialist Hospital and Research Center-Riyadh

08:42 – 08:50 CEST

SO-28: FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable mCRC patients: updated and overall survival results of the phase II randomized AtezoTRIBE study

Abstract Presenter:

08:50 – 08:58 CEST

SO-29: Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E+C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis

Abstract Presenter: – Vall d’Hebron University Hospital

08:58 – 09:06 CEST

SO-30: RAS status in circulating-tumor DNA after chemotherapy in RAS mutant mCRC: the RASMEX study (JACCRO CC-17)

Abstract Presenter:

09:06 – 09:14 CEST

SO-31: Comprehensive genomic profiling of tumor tissue and plasma circulating tumor DNA in RAS/BRAFV600E wild type metastatic colorectal cancer patients: initial findings from the CAPRI 2-GOIM trial

Abstract Presenter:

09:14 – 09:25 CEST

Discussant: SO-28, SO-29, SO-30, SO-31

Discussant: – Tampere and Kaolinska University Hospitals; Karolinska Institutet

08:15 – 09:25 CEST

Session XXI: Artificial Intelligence in GI Oncology

Chair: – Medical Oncology Department, Oncology Institute of Southern Switzerland

Chair: – Luxembourg Medical Center

08:15 – 08:50 CEST

Artificial Intelligence in GI Oncology

Speaker: – Academie nationale. de médecine France

08:50 – 09:15 CEST

Artificial Intelligence in Radiology/ Imaging

Speaker: – American Hospital of Paris

09:15 – 09:25 CEST

Q&A and Panel Discussion

Moderator: – Medical Oncology Department, Oncology Institute of Southern Switzerland

Moderator: – Luxembourg Medical Center

Panelist: – American Hospital of Paris

Panelist: – Academie nationale. de médecine France

08:30 – 09:25 CEST

Session XXII: Surgical Advances in GI Oncology

Chair: – Gustave Roussy, Université Paris-Saclay

Chair: – Vanderbilt-Ingram Cancer Center

Chair: – Clinic Favoriten, Dept Surgery, HPB Center, health network Vienna Sigmund Freud Private University Vienna

08:30 – 08:50 CEST

Transplantation in Primary Liver Tumors

Speaker: – University of Milan, Department of Hemato-Oncology

08:50 – 09:10 CEST

Transplantation in NETs and CRC

Speaker: – Paul Brousse Hospital

09:10 – 09:25 CEST

Complex Liver Resections for Liver Metastases

Speaker: – Department of Digestive and Hepatobiliary/Pancreatic Surgery, Groeninge Hospital, Kortrijk

09:30 – 13:15 CEST

Session XXIII: Colorectal Cancer: Metastatic Disease

Chair: – Gustave Roussy, Université Paris-Saclay

Chair: – University Hospitals Leuven / KU Leuven

09:30 – 09:40 CEST

LBA-5: Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (mCRC): the phase 3 LEAP-017 study

Abstract Presenter:

09:40 – 09:50 CEST

Highlight Presentation of ASCO 2023 - Promising HER-2 Targeted Therapy

Speaker: – National Cancer Center Hospital East, Japan

09:50 – 09:55 CEST

Colorectal Cancer Management Across Different Continents: Asian Guidelines

Speaker: – National Cancer Center Hospital East, Japan

09:55 – 10:00 CEST

Colorectal Cancer Management Across Different Continents: ESMO Guidelines

Speaker: – Biomedical Research institute INCLIVA, University of Valencia, Hospital Clínico de Valencia

10:00 – 10:05 CEST

Colorectal Cancer Management Across Different Continents: NCCN Guidelines

Speaker: – Vanderbilt-Ingram Cancer Center

10:05 – 10:25 CEST

Colorectal Cancer Management Across Different Continents: Q&A and Panel Discussion

Chair: – Gustave Roussy, Université Paris-Saclay

Chair: – University Hospitals Leuven / KU Leuven

Panelist: – Biomedical Research institute INCLIVA, University of Valencia, Hospital Clínico de Valencia

Panelist: – Vanderbilt-Ingram Cancer Center

Panelist: – National Cancer Center Hospital East, Japan

10:25 – 10:33 CEST

SO-32: Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT).

Abstract Presenter:

10:33 – 10:41 CEST

SO-33: The effect of RAS/BRAF mutation status on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer – a post-hoc exploratory analysis of the randomized NORDIC9-study

Abstract Presenter: – Department of Clinical Research, University of Southern Denmark

10:41 – 11:00 CEST

Checkpoint Inhibitors in MSI-H Colorectal Cancer

Speaker: – Vanderbilt-Ingram Cancer Center

11:00 – 11:20 CEST

How to Make MSS Tumors More Sensitive for Immunotherapy?

Speaker: – Vall d’Hebron University Hospital

11:20 – 11:40 CEST

BRAF Mutant Tumors: Strategy and New Data

Speaker: – Università degli Studi della Campania Luigi Vanvitelli

12:10 – 12:45 CEST

Keynote Lecture: Early-Onset CRC

Keynote Speaker: – Rambam Health Care Campus

12:45 – 12:55 CEST

O-11: The genomic landscape of appendiceal adenocarcinoma revealed by 855 Whole Exome Sequences

Abstract Presenter:

12:55 – 13:05 CEST

O-12: NCI9673 (Part B): A multi-institutional ETCTN randomized phase II study of nivolumab with or without ipilimumab in refractory, metastatic squamous cell carcinoma of the anal canal

Abstract Presenter: – MD Anderson Cancer Center

13:05 – 13:15 CEST

Discussant: O-11, O-12

Discussant: – Instituto Alexander Fleming

11:40 – 12:10 CEST

Break and Poster Viewing

13:30 – 15:00 CEST

Lunch Symposium: Clinical Decision-making in Unresectable HCC: Tackling Patient Treatment Goals Supported by AstraZeneca

13:30 – 15:00 CEST

Lunch Symposium: Targeting HER2 mCRC: Emerging and Future Options Supported by Seagen

13:30 – 15:00 CEST

Lunch Symposium: The Current Colorectal Cancer Landscape and Considerations for Future Therapeutic Approaches Supported by Takeda

15:15 – 16:35 CEST

Session XXIV: GI Oncology: Past, Present, and Future

Chair: – University Hospitals Leuven / KU Leuven

Chair: – Vall d’Hebron University Hospital

Chair: – Gustave Roussy, Université Paris-Saclay

15:15 – 15:40 CEST

25 Years of Progress in NETs

Speaker: – Charite Universitätsmedizin Berlin

15:40 – 16:05 CEST

25 Years of Progress in Upper GI Cancer

Speaker: – Biomedical Research institute INCLIVA, University of Valencia, Hospital Clínico de Valencia

16:05 – 16:30 CEST

25 Years of Progress in Colorectal Cancer Treatment

Speaker: – IRCCS Ospedale San Martino IST

16:30 – 16:35 CEST

Concluding Remarks

Chair: – University Hospitals Leuven / KU Leuven

Chair: – Vall d’Hebron University Hospital

Chair: – Gustave Roussy, Université Paris-Saclay